Neoadjuvant mFOLFOX6 +/- Aflibercept in patients with T3-rectal cancer at low risk for local failure: a randomized phase II trial of the German Rectal Cancer Study Group (ACO/ARO/AIO 0214) - Hofheinz, R; Merx, K; Herrle, F (Oncol Res Treat, 2023)
V1018